CURRICULUM VITAE

UGO CAVALLARO, PhD

Education:

1983-1989	University of Florence (Italy), Program in Biology
1989	Degree (Italian Laurea) magna cum laude in Biological Sciences
1995	Ph.D. equivalent according to EMBO guidelines
2002	PhD (Italian "Dottorato di Ricerca") in Experimental Pathology

Educational activities

- Member of the Educational Committee, Dept. of Experimental Oncology, European Institute of Oncology, Milano.
- Member of the Educational Committee, European School of Molecular Medicine (www.semm.it), Milano.
- Lecturer, examiner and course organizer for the International PhD program of the European School of Molecular Medicine (SEMM).
- Supervisor and co-supervisor of several PhD students.
- Lecturer at PhD course of University of Copenhagen, Denmark.
- Lecturer at PhD course of Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.
- Co-Organizer of the 2nd IFOM-IEO Campus Meeting on Cancer, May 5-8, 2006.
- Co-Organizer of the SEMM workshop “Cell Migration: from Molecules to Organisms and Diseases”, May 12-14, 2007.

Current Research Grants

2019-2024 Grant from the Italian Association for International Cancer Research as Principal Investigator of the research project “Novel drivers and therapeutic targets in ovarian cancer stem cells”.

2020-2023 Grant from the Ovarian Cancer Research Alliance (OCRA, USA) as Coordinator of the research project "Interplay between ovarian cancer stem cells and the tumor microenvironment: Mechanisms, biological implications and therapeutic opportunities".

2023-2026 Grant from ERA PerMed (EU) as Coordinator of the research project "Personalising the clinical decision making in ovarian cancer through patient-derived in vitro models".

2024-2027 Grant from the Ovarian Cancer Research Alliance (OCRA, USA) as Collaborator of the research project "Defining the impact of DNA repair variants on immune-based therapy of ovarian cancer at scale".

2024-2026 Grant from from the Italian Ministry of Health (PNRR 2023) as Collaborator of the research project "Coupling multi-omics with organotypic models to unravel the pathobiology and explore vulnerabilities in low-grade serous ovarian cancer".

Professional experience

June 2016-present
Director, Unit of Gynecological Oncology Research, Program of Gynecological Oncology & Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.

February 2012
Research Director (DR), INSERM (French Ministries of Research and Health), France. Position declined.

January 2011-May 2016
Principal Investigator at the Molecular Medicine Program, Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.

September 2003-December 2010
Team Leader at IFOM (FIRC Institute of Molecular Oncology), IFOM-IEO Campus, Milan, Italy.

September 2001-August 2003
Assistant at the Institute of Biochemistry and Genetics, Medical Faculty, University of Basel, Switzerland.

May 1999-August 2001
Post-Doctoral fellow at the Research Institute of Molecular Pathology, Vienna, Austria.

December 1995-April 1999
Research Associate, Dibit, Scientific Institute H San Raffaele, Milano.

April 1992-November 1995
Graduate Student, Dibit, Scientific Institute H San Raffaele, Milano.

September 1991-March 1992
Visiting Scientist, Department of Molecular and Cellular Growth Biology, The Whittier Institute, La Jolla, California.

June 1991-August 1991
Visiting Scientist, Microbiology Institute, University of Copenhagen.

September 1990-May 1991
Graduate student, Department of Biological and Technological Research (Dibit), Biotechnology Unit, Scientific Institute H San Raffaele, Milano.

September 1987-September 1990
Undergraduate Student, Unit of Human Genetics, Pediatric Department, University of Florence.

Publications

1. Battistini C, Kenny HA, Nieddu V, Melocchi V, Decio A, Gatto A, Ghioni M, Porta FM, Giavazzi R, Colombo N, Bianchi F, Lengyel E, and **Cavallaro U.** (2024) Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. *Cell Death Dis*, doi: 10.1038/s41419-024-06767-7.
2. Battistini C, Kenny HA, Nieddu V, Melocchi V, Decio A, Gatto A, Ghioni M, Porta FM, Giavazzi R, Colombo N, Bianchi F, Lengyel E, and **Cavallaro U.** (2023) Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. *bioRxiv*, doi: 10.1101/2023.10.30.564779.
3. Nieddu, V., Melocchi V., Battistini C., Franciosa G., Lupia M., Stellato C., Bertalot G., Olsen J.V., Colombo N., Bianchi F., and **Cavallaro U.** (2023) Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer. *Cell Death Dis*, 14:220. doi: 10.1038/s41419-023-05760-w.
4. Nieddu, V., Melocchi V., Battistini C., Franciosa G., Lupia M., Stellato C., Bertalot G., Olsen J.V., Colombo N., Bianchi F., and **Cavallaro U.** (2023) Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer. *bioRxiv*, doi: 10.1101/2022.12.06.519263.
5. Battistini C. and **Cavallaro U.** (2023). Patient-Derived In Vitro Models of Ovarian Cancer: Powerful Tools to Explore the Biology of the Disease and Develop Personalized Treatments. *Cancers*, 15:368. doi: 10.3390/cancers15020368.
6. Tricomi J., Landini L., Nieddu V., **Cavallaro U.**, Baker J.G., Papakyriakou A., and Richichi B. (2022). Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships. *Eur J Med Chem*, 246:114961. doi: 10.1016/j.ejmech.2022.114961.
7. Boylan K.L.M., Petersen A., Starr T.K., Pu X., Geller M.A., Bast R.C. Jr, Lu K.H., **Cavallaro U.**, Connolly D.C., Elias K.M., Cramer D.W., Pejovic T., Skubitz A.P.N. (2022). Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. *Cancers*, 14(13):3077. doi: 10.3390/cancers14133077.
8. Nagaraj V., Mikhail M., Baronio M., Gatto A., Nayak A., Theis T., **Cavallaro U.** and Schachner M. (2022). Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro. *Biomolecules*, 12(3):439. doi: 10.3390/biom12030439.
9. Lupia M., Melocchi V., Bizzaro F., Lo Riso P., Dama E., Baronio M., Ranghiero A., Barberis M., Bernard L., Bertalot G., Giavazzi R., Testa G., Bianchi F., and **Cavallaro U** (2022). Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities. *Int J Cancer*, 151(2):240-254. doi: 10.1002/ijc.33983.
10. Velletri T., Villa C.E., Cilli D., Barzaghi B., Lo Riso P., Lupia M., Luongo R., López-Tobón A., De Simone M., Bonnal R.J.P., Marelli L., Piccolo S., Colombo N., Pagani M., **Cavallaro U.**, Minucci S., and Testa G. (2022) Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. *Cell Death Diff*er, 29(3):614-626. doi: 10.1038/s41418-021-00878-w.
11. Bizzaro F., Fuso Nerini I., Taylor M.A., Anastasia A., Russo M., Damia G., Guffanti F., Guana F., Ostano P., Minoli L., Hattersley M.M., Arnold S., Ramos-Montoya A., C. Williamson S.C, Galbiati A., Urosevic J., Leo E., **Cavallaro U.**, Ghilardi C., Barry S.T., Bani M.R., and Giavazzi R. (2021) VEGF pathway

inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. *J Hematol Oncol* 14:186. doi: 10.1186/s13045-021-01196-x.

12. Giordano M., Decio A., Battistini C., Baronio M., Bianchi F., Villa A., Bertalot G., Freddi S., Lupia M., Jodice M.G., Ubezio P., Colombo N., Giavazzi R., and **Cavallaro U**. (2021) L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling. *J Exp Clin Cancer Res* 40(1):319. doi: 10.1186/s13046-021-02117-z.
13. Giordano M. and **Cavallaro U**. (2020) Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells. *J Clin Med* 16;9:1502. doi: 10.3390/jcm9051502.
14. Lo Riso P., Villa C.E., Gasparoni G., Vingiani A., Luongo R., Manfredi A., Jungmann A., Bertolotti A., Borgo F., Garbi A., Lupia M., Laise P., Das V., Pruneri G., Viale G., Colombo N., Manzo T., Nezi L., **Cavallaro U.**, Cacchiarelli D., Walter J., and Testa G. (2020) A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. *Genome Med* 12:94. doi: 10.1186/s13073-020-00786-7.
15. Kakogiannos N., Ferrari L., Giampietro C., Scalise A.A., Maderna C., Ravà M., Taddei A., Lampugnani M.G., Pisati F., Malinverno M., Martini E., Costa I., Lupia M., **Cavallaro U.**, Beznoussenko G.V., Mironov A.A., Fernandes B., Rudini N., Dejana E., Giannotta M. (2020) JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function. *Circ Res* 127:1056-1073.
16. Zamai M., Trullo A., Arza E., **Cavallaro U.**, Caiolfa V.R. (2019) Oligomerization Dynamics of Cell Surface Receptors in Living Cells by Total Internal Reflection Fluorescence Microscopy Combined with Number and Brightness Analysis. *J Vis Exp*, doi: 10.3791/60398.
17. Angiolini F., Belloni E., Giordano M., Campioni M., Forneris F., Paronetto M.P., Lupia M., Brandas C., Pradella D., Di Matteo A., Giampietro C., Jodice, G., Luise C., Bertalot G., Freddi S., Malinverno M., Irimia M., Moulton J., Summerton J., Chiapparino A., Ghilardi C., Giavazzi R., Nyqvist D., Gabellini D., Dejana E., **Cavallaro U.***, and Ghigna C.* (2019) A Novel L1CAM Isoform with Angiogenic Activity Generated by NOVA2-mediated Alternative Splicing. *eLife*, 8. pii: e44305. *co-senior authorship
18. Zamai M., Trullo A., Giordano M., Corti V., Arza Cuesta E., Francavilla C., **Cavallaro U.***, and Caiolfa V.R.* (2018) Number and Brightness analysis in live cells reveals that NCAM and FGF2 elicit different assembly and dynamics of FGFR1. *J. Cell Sci.*, 132:jcs.220624 *co-senior authorship
19. Guffanti F., Fratelli M., Ganzinelli M., Bolis M., Ricci F., Bizzaro F., Chilà R., Sina P.F., Fruscio R., Lupia M., **Cavallaro U.**, Cappalletti M.R., Generali D., Giavazzi R., and Damia G. (2018) Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. *Oncotarget*, 9:24707-24717.
20. Noberini R., Osti D., Miccolo C., Richichi C., Lupia M., Corleone G., Hong S.P., Colombo P., Pollo B., Fornasari L., Pruneri G., Magnani L., **Cavallaro U.**, Chiocca S., Minucci S., Pelicci G., and Bonaldi T. (2018) Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. *Nucleic Acids Res.*, 46:3817-3832.
21. Morini M.F., Giampietro C., Corada M., Pisati F., Lavarone E., Cunha S.I., Conze L.L., O'Reilly N., Joshi D., Kjaer S., George R., Nye E., Ma A., Jin J., Mitter R., Lupia M., **Cavallaro U.**, Pasini D., Calado D.P., Dejana E., Taddei A. (2018) VE-

Cadherin-Mediated Epigenetic Regulation of Endothelial Gene Expression. *Circ. Res.*, 122:231-245.

22. Lupia M., Angiolini F., Bertalot G., Freddi S., Sachsenmeier K.F., Chisci E., Kutryb-Zajac B., Confalonieri C., Smolenski R.T., Giovannoni R., Colombo N., Bianchi F., and **Cavallaro U.** (2018) CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells. *Stem Cell Reports*, 10:1412-1425.
23. Francavilla C., Lupia M., Tsafou K., Villa A., Kowalczyk K., Rakownikow Jersie-Christensen R., Bertalot G., Confalonieri S., Brunak S., Jensen L.J., **Cavallaro U.***, Olsen J.V.* (2017) Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer. *Cell Rep.*, 18:3242-3256. * co-senior authorship
24. Lupia M. and **Cavallaro U.** (2017) Ovarian cancer stem cells: still an elusive entity? *Mol. Cancer*, 16(1):64. doi: 10.1186/s12943-017-0638-3.
25. Angiolini F. and **Cavallaro U.** (2017) The pleiotropic role of L1CAM in tumor vasculature. *Int. J. Mol. Sci.*, 18(2). doi:10.3390/ijms18020254.
26. **Cavallaro U.** (2016) L1 in tumor vasculature. *Oncotarget*, 7:11744-11745.
27. Wollscheid H.P., Biancospino M., He F., Magistrati E., Molteni E., Lupia M., Soffientini P., Rottner K., **Cavallaro U.**, Pozzoli U., Mapelli M., Walters K.J., Polo S. (2016) Myosin VI diverse functions elucidated by an alternatively spliced alpha helix domain. *Nat. Struct. Mol. Biol.*, 23:300-388.
28. Magrini E., **Cavallaro, U.***, and Bianchi F.* (2015) Microarray profiling of L1-overexpressing endothelial cells reveals STAT3 activation via IL-6/IL-6Rα axis. *Genom. Data*, 4:137-139. * co-senior authorship
29. Angiolini F. and **Cavallaro U.** (2014) The control of tumor vessels: what you would not expect from a neural adhesion molecule. *Mol Cell Oncol.*, 2: e982045.
30. Magrini E., Villa A., Angiolini F., Doni A., Mazzarol G., Rudini N., Maddaluno L., Komuta M., Topal B., Prenen H., Schachner M., Confalonieri S., Dejana E., Bianchi F., Mazzone M., and **Cavallaro U.** (2014) Endothelial deficiency of adhesion molecule L1 reduces tumor angiogenesis and promotes vessel normalization. *J. Clin. Invest.*, 124:4335-4350.
31. Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, **Cavallaro U**, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, and Bertolini F. (2014) *Ecancermedicalscience*. 8:463
32. Francavilla C., Rigbolt K.T., Emdal K.B., Carraro G., Vernet E., Bekker-Jensen D.B., Streicher W., Wikström M., Sundström M., Bellusci S., **Cavallaro U.**, Blagoev B., Olsen J.V. (2013). Functional Proteomics Defines the Molecular Switch Underlying FGF Receptor Trafficking and Cellular Outputs. *Mol Cell*, 51:707-722.
33. Giampietro C., Taddei A., Corada M., Sarra-Ferraris G.M., Alcalay M., **Cavallaro U.**, Orsenigo F., Lampugnani M.G., and Dejana E. (2012) Overlapping and divergent signaling pathways of N-cadherin and VE-cadherin in endothelial cells. *Blood*, 119:2159-2170.
34. Cattaruzza S., Ozerdem U., Denzel M., Ranscht B., Bulian P., **Cavallaro U.**, Zanocco D., Colombatti A., Stallcup W.A., and Perris R. (2012) Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells. *Angiogenesis*, 16:309-327.

35. Colombo N. and **Cavallaro U.** (2011) The interplay between NCAM and FGFR signalling underlies ovarian cancer progression. *Ecancermedicalscience*.5:226.
36. Zecchini S., Bombardelli L., Decio A., Bianchi M., Mazzarol G., Sanguineti, F., Aletti G., Maddaluno L., Berezin V., Bock E., Casadio C., Viale G., Colombo N., Giavazzi R., and **Cavallaro U.** (2011) The adhesion molecule NCAM promotes ovarian cancer malignancy via FGFR signaling. *EMBO Mol Med*., 3:480-494.
37. Veggiani G., Ossolengo G., Aliprandi M., **Cavallaro U.**, de Marco A. (2011) Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1. *Biochem. Biophys. Res. Commun.*, 408:692-696.
38. **Cavallaro U.** and Dejana E. (2011) Adhesion molecule signaling*:* not always a sticky business. *Nat. Rev. Mol. Cell Biol.,* 12:189-197.
39. Bombardelli L. and **Cavallaro U.** (2010) Ig-CAMs: novel signaling players in epithelial ovarian cancer. *Int. J. Biochem. Cell Biol.*, 42:590-594.
40. Zecchini S. and **Cavallaro U.** (2010) Neural cell adhesion molecule in cancer: expression and mechanisms. *Adv. Exp. Med. Biol.*, 663:319-333.
41. Murakami M., Francavilla C., Sica A., Mantovani A., Matteoli G., Iliev I.D., Rescigno M., **Cavallaro U.**, and Dejana E. (2010) Inactivation of Junctional Adhesion Molecule-A enhances the antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration. *Cancer Res.*, 70(5):1759-1765.
42. Francavilla, C., Berezin V., Bock E., Ami D., de Marco A., Christofori G., and **Cavallaro U.** (2009). The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. *J. Cell Biol*., 187:1101-1116.
43. Francavilla, C. Maddaluno, L. and **Cavallaro U.** (2009). The functional role of cell adhesion molecules in tumor angiogenesis. *Semin. Cancer Biol*, 19:298-309.
44. Maddaluno L., Verbrugge S.E., Martinoli C., Matteoli G., Chiavelli A., Zeng Y., Williams E.D., Rescigno M., and **Cavallaro U.** (2009) The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells. *J. Exp. Med,*, 206:623-635.
45. Zecchini S., Bianchi M., Colombo N., Fasani R., Goisis, G., Casadio C., Viale G., Liu J., Herlyn M., Godwin A.K., Nuciforo P., and **Cavallaro U.** (2008) The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Implications for ovarian carcinoma progression. *Cancer Res.,* 68:1110-1118.
46. Francavilla C., Loeffler S., Piccini D., Kren A., Christofori G., and **Cavallaro U.** (2007) Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. *J. Cell Sci.*, 120: 4388-4394.
47. Kren A., Baeriswyl V., Lehembre F., Wunderlin C., Strittmatter K., Antoniadis H., Fässler R., **Cavallaro U.**, and Christofori G. (2007) Increased tumor cell dissemination and cellular senescence in the absence of β1-integrin function. *EMBO J.*, 26: 2832–2842.
48. Liebner S.*, **Cavallaro U.***, and Dejana E. (2006) The multiple languages of endothelial cell-to-cell communication. *Arterioscler. Thromb. Vasc. Biol.*, 26:1431-1438. * co-first authorship
49. **Cavallaro U.**, Liebner S., and Dejana E. (2006) Endothelial cadherins and tumor angiogenesis. *Exp. Cell Res.*, 312:659-667.
50. Crinic I., Strttimatter K., **Cavallaro U.**, Kopfstein L., Jussila L., Alitalo K., and Christofori G. (2004) Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. *Cancer Res*, 64:8630-8638.

51. **Cavallaro U.** (2004) N-cadherin as an invasion promoter: a novel target for antitumor therapy? *Curr. Opin. Invest. Drugs*, 5:1274-1278.
52. **Cavallaro U.** and Christofori G. (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. *Nat. Rev. Cancer*, 4:118-132.
53. **Cavallaro U.** and Christofori G. (2004) Multitasking in tumor progression: signaling functions of cell adhesion molecules. *Ann. N.Y. Acad. Sci.*, 1014:58-66.
54. Galbiati F., Polastri L., Thorens B., Dupraz P., Fiorina P., **Cavallaro U.**, Christofori G., Davalli A.M. (2003) Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. *Endocrinology*, 144:1832-1841.
55. Galbiati F., Polastri L., Gregori S., Freschi M., Casorati M., **Cavallaro U.**, Fiorina P., Bertuzzi F., Zerbi A., Pozza G., Adorini L., Folli F., Christofori G., Davalli A.M. (2002) Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. *Endocrinology*, 143:4018-4030.
56. **Cavallaro U.**, Schaffhauser B., and Christofori G. (2002) Cadherins and tumor progression: is it all in a switch? *Cancer Lett.*, 176:123-128.
57. Wu Z., Mariotti M., **Cavallaro U.**, Soria M.R., and Maier J.A.M. (2002) Differential response to Tat and FGF-2 of two novel clonal populations derived from murine Kaposi-like lesions developing in *tat* transgenic mice. *Microvasc. Res.*, 63:19-26.
58. **Cavallaro U.**, and Christofori G. (2001) Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. *Biochim. Biophy. Acta*, 1552:39-45.
59. **Cavallaro U.**, Niedermeyer J., Fuxa M., and Christofori G. (2001) N-CAM modulates tumor cell-matrix adhesion by inducing FGF receptor signalling. *Nature Cell Biol.*, 3:650-657.
60. **Cavallaro U.**, Tenan M., Castelli V., Perilli A., Maggiano N., Van Meir E., Montesano R., Soria M.R., and Pepper M.S. (2001) The response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: relevance to the regulation of angiogenesis. *J. Cell. Biochem.*, 82:619-633.
61. **Cavallaro U.**, Perilli A., Da Costa S.R., Castelli V., and Soria M.R. (2001) FGF-2 promotes disassembly of actin cytoskeleton and shape changes in murine vascular cells. *Microvasc. Res.*, 61:211-214.
62. **Cavallaro U.** and Christofori G. (2000) Molecular mechanisms of tumor angiogenesis and tumor progression. *J. Neuro-Oncol.*, 50:63-70.
63. **Cavallaro U.**, Soria M.R., and Montesano R. (2000) Exogenous fibroblast growth factor-2 induces a transformed phenotype in vascular Kaposi's sarcoma-like cells. *Mol. Cell Biol. Res. Commun.*, 4:203-205.
64. **Cavallaro U.**, Castelli V., Del Monte U., and Soria M.R. (2000) Phenotypic alterations in senescent large-vessel and microvascular endothelial cells. *Mol. Cell Biol. Res. Commun.*, 4:117-121.
65. **Cavallaro U.**, Castelli V., Perilli A., Dossi R., Giavazzi R., Pepper M.S., Soria M.R., and Montesano R. (2000) Characterization of novel clonal murine endothelial cell lines with an extended life span. *In Vitro Cell. Dev. Biol. Anim.*, 36:299-308.
66. Davalli A.M., Scaglia L., Brevi M., Sanvito F., Freschi M., **Cavallaro U.**, Parlow A.F., and Pontiroli A. (1999) Pituitary cotransplantation significantly improves the performance, insulin content, and vascularization of renal subcapsular islet graft. *Diabetes*, 48:59-65.

67. **Cavallaro U.**, Wu Z., Di Palo A., Montesano R., Pepper M.S., Maier J.A.M., and Soria M.R. (1998) FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor. *FASEB J.*, 12:1027-1034.
68. Wu Z., **Cavallaro U.**, Marchisio P.C., Soria M.R., and, Maier J.A.M. (1998) Fibronectin modulates the effects of HIV-1 Tat on the growth of murine Kaposi's sarcoma-like cells through the downregulation of tyrosine phosphorylation. *Am. J. Pathol.,* 152:1599-1605.
69. **Cavallaro U.**, Mariotti M., Wu Z., Soria M.R., and Maier J.A.M. (1997) Fibronectin modulates the endothelial response to HIV-1 Tat. *AIDS Res. Hum. Retroviruses*, 13: 1341-1348.
70. Fabbrini M.S., Rappocciolo E., Carpani D., Solinas M., Valsasina B., Breme U., **Cavallaro U.**, Nykjær A., Rovida E., Legname G., and Soria M.R. (1997) Characterization of a saporin isoform with lower ribosome-inhibiting activity. *Biochem. J.*, 322: 719-727.
71. Maier J.A.M., Mariotti M., Meneghin L., **Cavallaro U.**, Wu Z., Massazza G., Campioni D., Corallini A., Barbanti-Brodano G., and Soria M.R. (1996) Fibroblast growth factor-2, and not the HIV-Tat protein, is responsible for the protease activity of tumor cells isolated from BK virus/*tat* transgenic mice. *Fibrinolysis*, 10: 309-315.
72. **Cavallaro U.**, Gasparini G.P., Soria M.R., and Maier, J.A.M. (1996) Spindle cells isolated from Kaposi's sarcoma-like lesions of BKV/*tat* transgenic mice co-express markers of various cell types. *AIDS*, 10: 1211-1219.
73. **Cavallaro U.**, and Soria M.R. (1995) Targeting plant toxins to the urokinase and α_2-macroglobulin receptors. *Semin. Cancer Biol.*, 6:269-278.
74. **Cavallaro U.**, Nykjær A., and Soria M.R. (1995). α_2-Macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. *Eur. J. Biochem.*, 232: 165-171.
75. Conese M., **Cavallaro U.**, Olson D., Soria M.R., and Blasi F. (1995). PMA-induced down regulation of the receptor for α_2-macroglobulin in human U937 cells. *FEBS Lett.*, 358: 73-78.
76. Blasi F., Conese M., Møller L.B., Pedersen N., **Cavallaro U.**, Cubellis M.V., Fazioli F., Hernandez-Marrero L., Limongi P., Muñoz-Canoves P., Resnati M., Riittinen L., Sidenius N., Soravia E., Soria M.R., Stoppelli M.P., Talarico D., Teesalu T., Valcamonica S. (1994) The urokinase receptor: structure, regulation and inhibitor-mediated internalization. *Fibrinolysis*, 8, Suppl.1: 182-188.
77. Soria M.R., **Cavallaro U**, del Vecchio A., and Lappi D.A. (1994). Targeting of saporin to urokinase receptors. *J. Cell. Biochem.*, Suppl.18A: EZ507.
78. **Cavallaro U.**, del Vecchio A., Tazzari P.L., and Soria M.R. (1993). Targeting of cytotoxic conjugates to Kaposi's sarcoma-derived cells. *Drug Delivery*, 1:119-124.
79. **Cavallaro U.**, del Vecchio A., Lappi D.A., and Soria M.R. (1993). A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. *J. Biol. Chem.*, 268: 23186-23190.
80. Barthelemy I., Prieto I., **Cavallaro U.**, Benatti L., Solinas M., Soria M.R., and Lappi D.A.(1993). The expression of saporin, a ribosome-inactivating protein from the plant *Saponaria officinalis*, in *Escherichia coli*. *J. Biol. Chem.*, 268: 6541-6548.